Trial Profile
Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Dec 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 14 Nov 2022 Results assessing long-term efficacy and safety of subcutaneous tocilizumab in patients with polyarticular or systemic juvenile idiopathic arthritis, presented at the ACR Convergence 2022.
- 30 Jul 2022 This trial has been discontinued in Spain, according to European Clinical Trials Database record.
- 22 Feb 2022 Status changed from active, no longer recruiting to completed.